BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin
GlobeNewswire Inc.
BeyondSpring, a clinical-stage biopharmaceutical company, will present data on its lead anti-cancer asset, Plinabulin, at the 2024 World Conference on Lung Cancer and ESMO Congress 2024. The presentations will focus on the final efficacy data of Plinabulin and docetaxel combination in EGFR wild-type 2L/3L non-small cell lung cancer, as well as safety and efficacy results from other studies.
Continue Reading